Table 3 Proportions of the different histological types of malignant CMT diagnosed between 2011 and 2020

Complex carcinoma

40.16% (38.55%; 41.78%)

0.0014

Tubulopapillary carcinoma

24.72% (23.31%; 26.16%)

0.0131

Carcinoma arising in mixed benign tumour

20.80% (19.48%; 22.16%)

0.0044

Solid carcinoma

6.86% (6.06%; 7.73%)

0.0084

Carcinosarcoma

1.89% (1.47%; 2.39%)

0.0502

Anaplastic carcinoma

1.19% (0.87%; 1.61%)

0.1250

Squamous cell carcinoma

1.11% (0.79%; 1.51%)

0.4040

Carcinoma NOS^a

0.61% (0.38%; 0.92%)

0.1450

Osteosarcoma

0.56% (0.34%; 0.86%)

0.4110

Fibrosarcoma

0.42% (0.23%; 0.69%)

0.0477

Ductal carcinoma

0.39% (0.21%; 0.65%)

0.0019

Haemangiosarcoma

0.39% (0.21%; 0.65%)

0.2370

Sarcoma NOS^b

0.19% (0.08%; 0.40%)

0.0446

In situ carcinoma

0.17% (0.06%; 0.36%)

0.1560

Inflammatory carcinoma

0.17% (0.06%; 0.36%)

0.4150

Carcinoma and malignant myoepithelioma

0.11% (0.03%; 0.28%)

0.6620

Malignant myoepithelioma

0.11% (0.03%; 0.28%)

0.1430

Lipid-rich (secretory) carcinoma

0.08% (0.02%; 0.24%)

0.1610

Intraductal papillary carcinoma

0.06% (0.01%; 0.20%)

0.9460

Micropapillary invasive carcinoma

0.03% (0.00%; 0.15%)

0.8270